US Broker Ratings

CRISPR Therapeutics AG (CRSP) Investor Outlook: Uncovering a 44% Potential Upside in Gene Editing Pioneer

For investors keeping a close eye on the biotechnology sector, CRISPR Therapeutics AG (NASDAQ: CRSP) presents a compelling opportunity, particularly given its groundbreaking work in gene editing. With a market..

Organon & Co. (OGN) Stock Analysis: Unveiling a 33% Potential Upside Amidst Analyst Divergence

As Organon & Co. (NYSE: OGN) navigates the ever-evolving healthcare landscape, investors are drawn to the stock’s potential upside of 33.29%, as highlighted by the average target price of $9.36...

ACADIA Pharmaceuticals Inc. (ACAD) Stock Analysis: High Growth Potential with 34.95% ROE in the Biotech Sector

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) stands as a noteworthy player in the biotechnology sector, particularly for investors with an eye on innovative therapies for central nervous system (CNS) disorders and..

Arrowhead Pharmaceuticals (ARWR): Investor Outlook on a Biotech Gem with a $9.46 Billion Market Cap

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) stands as a noteworthy contender in the biotechnology sector, given its robust market capitalization of $9.46 billion. This California-based company is making significant strides in..

Veracyte, Inc. (VCYT) Stock Report: Analyst Ratings Highlight a Promising 9.12% Upside

Veracyte, Inc. (NASDAQ: VCYT) stands out in the healthcare sector, particularly within the diagnostics and research industry, with its innovative genomic diagnostic solutions. Headquartered in South San Francisco, California, Veracyte..

LivaNova PLC (LIVN) Investor Outlook: Exploring a Promising 9.58% Potential Upside

LivaNova PLC (NASDAQ: LIVN), a key player in the medical devices industry, is drawing investor attention with its noteworthy potential upside of 9.58%. As a company headquartered in London, UK,..

Perrigo Company plc (PRGO) Stock Analysis: Exploring a 63.55% Potential Upside in the Healthcare Sector

Perrigo Company plc (NYSE: PRGO), a prominent player in the healthcare sector, is capturing investor attention with a notable potential upside of 63.55%, as highlighted by its average target price...

DENTSPLY SIRONA Inc. (XRAY) Stock Analysis: Evaluating a 13.16% Potential Upside Amidst Market Challenges

DENTSPLY SIRONA Inc. (NASDAQ: XRAY) stands as a significant player in the healthcare sector, specifically within the medical instruments and supplies industry. With a rich history dating back to 1877,..

Alvotech (ALVO) Stock Analysis: Unpacking a Potential 310% Upside in the Biosimilar Market

Alvotech (NASDAQ: ALVO) is emerging as a dynamic player in the healthcare sector, specifically within the specialty and generic drug manufacturing industry. Based in Luxembourg, the company is making strides..

Soleno Therapeutics, Inc. (SLNO) Investor Outlook: Analyzing a Potential 118% Upside

Soleno Therapeutics, Inc. (NASDAQ: SLNO) is making waves in the biotechnology sector with its focus on developing novel therapies for rare diseases. With a current market capitalization of $2.79 billion,..

Prestige Consumer Healthcare Inc. (PBH) Stock Analysis: Exploring a 26.95% Upside Potential

Prestige Consumer Healthcare Inc. (NYSE: PBH) presents a compelling opportunity for investors seeking exposure in the healthcare sector, specifically within the drug manufacturing segment. With a market capitalization of $3.02..

Alkermes plc (ALKS): Investor Outlook Reveals 53% Potential Upside with Strong Buy Ratings

Alkermes plc (NASDAQ: ALKS), a prominent player in the biopharmaceutical sector, is drawing significant attention from investors, thanks to its robust product pipeline and impressive analyst ratings. Headquartered in Dublin,..

RadNet, Inc. (RDNT) Stock Analysis: Exploring a 24% Potential Upside with Strong Buy Ratings

RadNet, Inc. (NASDAQ: RDNT), a prominent player in the healthcare sector specializing in diagnostics and research, presents an intriguing opportunity for investors seeking growth in the fast-evolving field of medical..

TG Therapeutics, Inc. (TGTX): Investor Outlook and 41% Upside Potential

TG Therapeutics, Inc. (NASDAQ: TGTX) stands as a formidable player within the biotechnology sector, with a market capitalization of $4.98 billion. Specializing in the acquisition and development of innovative treatments..

Lantheus Holdings, Inc. (LNTH): Investor Outlook on a Promising 23.52% Potential Upside

Lantheus Holdings, Inc. (NASDAQ: LNTH) is capturing the attention of investors with its compelling market performance and promising growth potential. As a key player in the healthcare sector, specifically within..

Rhythm Pharmaceuticals, Inc. (RYTM) Investor Outlook: Navigating a 20.33% Potential Upside Amidst Strong Buy Ratings

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) stands as a compelling player in the biotechnology sector, particularly for investors eyeing potential upside in the healthcare industry. Based in Boston, Massachusetts, Rhythm Pharmaceuticals..

BrightSpring Health Services (BTSG) Stock Analysis: Exploring a 12.39% Upside Amidst Robust Revenue Growth

BrightSpring Health Services, Inc. (BTSG), a key player in the healthcare sector, has captured investor attention with its significant revenue growth and a promising potential upside. As an essential provider..

Bio-Techne Corp (TECH) Stock Analysis: Exploring a 19% Upside Potential

Bio-Techne Corporation (NASDAQ: TECH), a prominent player in the healthcare sector, has been making waves with its innovative contributions to the biotechnology industry. Headquartered in Minneapolis, Minnesota, Bio-Techne is a..

Bausch + Lomb Corporation (BLCO) Stock Report: Analyzing the Eye Health Giant’s Growth Potential

Bausch + Lomb Corporation (NYSE: BLCO) stands as a stalwart in the healthcare sector, particularly within the medical instruments and supplies industry. With its headquarters in Vaughan, Canada, the company..

Elanco Animal Health (ELAN) Stock Analysis: A Strong Buy with 15.98% Upside Potential

Elanco Animal Health Incorporated (NYSE: ELAN), a leader in the healthcare sector, specifically within the niche of specialty and generic drug manufacturing for animals, is capturing investor attention with a..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds